Dateline City:
CHICAGO
Overall Response Rate of 20 Percent for Pembrolizumab as Single Agent in Patients with Advanced Head and Neck Cancer
Merck Initiating Phase 3 Study in Advanced Head and Neck Cancer with Pembrolizumab Versus Standard of Care in Q3 2014 (KEYNOTE-040)
Additional 110 Patients with Advanced Head and Neck Cancer to be Enrolled in KEYNOTE-012 with Assessment of PD-L1 Tumor Levels Planned
Pembrolizumab Announced as New Generic Name for MK-3475
CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the first presentation of early findings from a Phase 1b
study (KEYNOTE-012) evaluating pembrolizumab (MK-3475), Mercks
investigational anti-PD-1 antibody, as a single-agent (monotherapy) in
patients with PD-L1 positive, advanced head and neck cancer.
Language:
English
Contact:
MerckMedia Contacts:Ian McConnell, (973) 901-5722orClaire Mulhearn, (908) 423-7425orInvestor Contacts:Carol Ferguson, (908) 423-4465orJustin Holko, (908) 423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more